• Jonathan Shiek

Moderna’s Spikevax Becomes 7th Covid-19 Vaccine To Join Malaysia’s Immunisation Lineup

According to Health DG Dr. Noor Hisham Abdullah, Moderna’s Spikevax has officially gotten the green light by the Drug Control Authority, and it will be joining the immunisation lineup alongside Pfizer-BioNTech, Sinovac, AstraZeneca, Johnson & Johnson, CanSinoBio, and Sinopharm.

“The meeting agreed to give conditional registration approval for emergency use to the ‘Spikevax 0.20 mg/ml Dispersion for Injection’ mRNA vaccine (nucleoside modified) product,” said the Health DG.

It is still not decided whether the U.S. developed vaccine will be included in the National Covid-19 Immunisation Programme (PICK) or go straight to the private market. A quick intro into Moderna’s Spikevax, it is also known as mRNA-1237, which is the second mRNA vaccine to hit the market after Pfizer.

The vaccine prides itself for an efficacy rate of 94% and just this week, data revealed that recipients retained protection of 93% against the virus after 6 months. The data is considerably good compared to Pfizer’s mRNA shot which decreased to 86% effectiveness after 6 months as well.


#covid19 #Moderna #Spikevax

0 views0 comments